ArticleJournal of clinical medicine2022
Magnetic Resonance for Differential Diagnosis of Left Ventricular Hypertrophy: Diagnostic and Prognostic Implications.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- Curriculum-Based Deep Learning for Automated Segmental Left Ventricular Hypertrophy Classification Using Short-Axis Echocardiography.Diagnostics (Basel, Switzerland) · 2026Article
- Non-Ischemic Pattern of LGE After COVID-19 Correlates More with Severity of Acute Illness than with Long-Term Myocardial Dysfunction.Journal of clinical medicine · 2025Article
- Regulatory mechanisms of exercise-induced physiological cardiac hypertrophy: progress and prospects.Frontiers in cardiovascular medicine · 2025Review
- The Depiction of Hypertension in Heart Imaging Examinations: An Up-to-Date Review of the Evidence.Vascular health and risk management · 2023Review
- Electrocardiographic Parameters Associated with Adverse Outcomes in Children with Cardiomyopathies.Journal of clinical medicine · 2022Article
- Cardiac Magnetic Resonance in Fabry Disease: Morphological, Functional, and Tissue Features.Diagnostics (Basel, Switzerland) · 2022Review
- Post-Mortem Cardiac Magnetic Resonance in Explanted Heart of Patients with Sudden Death.International journal of environmental research and public health · 2022Article
- Usefulness of Longitudinal Strain Adjusted to Regional Thickness in Hypertrophic Cardiomyopathy.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeft ventricular hypertrophy (LVH) may be due to different causes, ranging from benign secondary forms to severe cardiomyopathies. Transthoracic Echocardiography (TTE) and ECG are the first-level examinations for LVH diagnosis. Cardiac magnetic resonance (CMR) accurately defines LVH type, extent and severity.
objectivesto evaluate the diagnostic and prognostic role of CMR in patients with TTE and/or ECG evidence of LVH.
methodsWe performed CMR in 300 consecutive patients with echocardiographic and/or ECG signs of LVH.
resultsOverall, 275 patients had TTE evidence of LVH, with initial suspicion of hypertrophic cardiomyopathy (HCM) in 132 (44%), cardiac amyloidosis in 41 (14%), hypertensive LVH in 48 (16%), aortic stenosis in 4 (1%), and undetermined LVH in 50 (16%). The initial echocardiographic diagnostic suspicion of LVH was confirmed in 172 patients (57.3%) and changed in 128 patients (42.7%,
conclusionsCMR changed echocardiographic suspicion in almost half of patients with LVH. In the subgroup of patients with abnormal ECG, CMR identified LVH (particularly HCM) in 80% of patients. This study highlights the indication of CMR to better characterize the type, extent and severity of LVH detected at echocardiography and suspected with ECG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.